# Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers

> **NCT02542813** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 16 (actual)

## Conditions studied

- Postpartum Hemorrhage

## Interventions

- **DRUG:** IM oxytocin 10 IU
- **DRUG:** IH oxytocin 50 mcg
- **DRUG:** IH oxytocin 200 mcg
- **DRUG:** IH oxytocin 400 mcg
- **DRUG:** IH oxytocin 600 mcg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02542813
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-14
- **Primary completion:** 2015-12-16
- **Final completion:** 2015-12-16
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02542813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02542813, "Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02542813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*